Chronic Spontaneous Urticaria Market Report 2024

The chronic spontaneous urticaria market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed in the historic period can be attributed to several factors, advancements in diagnostic tools, increased awareness among healthcare professionals, support from patient advocacy groups, ongoing studies and clinical trials investigating new therapies, and rising healthcare expenditure.

The chronic spontaneous urticaria market size is expected to see strong growth in the next few years. It will grow to $2.84 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. In the forecast period, growth can be attributed to several factors, an increasing number of diagnosed cases of chronic spontaneous urticaria (CSU), expansion of the patient pool, development of healthcare infrastructure, supportive regulatory environments promoting patient-centric care models, and economic growth in emerging markets. Major trends anticipated during this period include technological innovations, advancements in biological therapies, personalized medicine approaches, the integration of telemedicine and digital health solutions, advancements in diagnostic tools leveraging AI and machine learning, and a rise in drug approvals and launches.

The anticipated rise in alcohol consumption is expected to drive growth in the chronic spontaneous urticaria market moving forward. Factors contributing to increased alcohol consumption include social norms, stress, advertising, affordability, and availability. For some individuals, alcohol consumption can exacerbate symptoms of chronic spontaneous urticaria, leading to heightened episodes of hives and swelling. For example, rehabs.UK reported in February 2024 that 55% of men and 41% of women in the UK consume alcohol weekly, with 8% of men and 5% of women reporting near-daily alcohol consumption. Between 2021 and 2022, there were 342,795 hospital admissions attributed solely to alcohol, resulting in a rate of 626 admissions per 100,000 people. Therefore, the increasing consumption of alcohol is a driving force behind the growth of the chronic spontaneous urticaria market.

Leading companies in the chronic spontaneous urticaria market are focusing on developing advanced next-generation monoclonal anti-immunoglobulin E (IgE) antibodies to enhance treatment efficacy and reduce dosing frequency. These antibodies are designed to improve treatment outcomes and prolong dosing intervals for conditions such as chronic spontaneous urticaria. For instance, in January 2021, Novartis AG, a pharmaceutical company based in Switzerland, received FDA approval for ligelizumab (QGE031) with Breakthrough Therapy designation for treating chronic spontaneous urticaria in patients who do not adequately respond to H1-antihistamine treatment. Ligelizumab represents a significant advancement in the treatment of chronic spontaneous urticaria.

In March 2022, Novan Inc., a specialty dermatology company in the US, acquired EPI Health LLC to strengthen its commercial infrastructure in preparation for potential FDA approval of its lead product candidate, SB206 (berdazimer gel 10.3%), for molluscum contagiosum treatment. EPI Health LLC is known for providing Xyzal (levocetirizine) for managing uncomplicated skin manifestations.

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic spontaneous urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent hives (raised, red, itchy welts) and angioedema (swelling) persisting for more than six weeks, without a clear external trigger. The exact cause of CSU is often unknown but may involve an autoimmune mechanism where the body's immune system erroneously targets healthy skin cells. Treatment primarily aims at managing symptoms, typically starting with antihistamines and, in more severe cases, other medications such as biologics.

The main treatments for chronic spontaneous urticaria include medication, phototherapy, and other interventions. Medication for CSU usually begins with antihistamines as the first-line approach, with options varying from non-sedating to sedating types based on the severity of symptoms and individual patient response. These medications can be administered orally, topically, parenterally, or through other routes. Diagnosis involves physical examination, blood tests, and allergy testing, and the treatments are utilized across various settings including hospitals, specialty clinics, home care settings, among others.

The chronic spontaneous urticaria research report is one of a series of new reports that provides chronic spontaneous urticaria market statistics, including the chronic spontaneous urticaria industry's global market size, regional shares, competitors with a chronic spontaneous urticaria market share, detailed chronic spontaneous urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the chronic spontaneous urticaria industry. This chronic spontaneous urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic spontaneous urticaria market consists of revenues earned by entities by providing services such as diagnostic services and medical consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic spontaneous urticaria market also includes sales of antihistamines, corticosteroids, and cyclosporine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.